Egalet Surrenders Some Early Gains After Challenging FDA For MorphaBond Exclusivity

Egalet Corp (NASDAQ:EGLT) shares are trading higher by $0.31 (7 percent) at $5.15 in Wednesday's session.

Before the open, the company announced its challenge to the FDA for MorphBond exclusivity is still being considered. That news instigated a modestly higher open and after a brief pullback, the issue found support just above Tuesday's close ($4.84) at $4.89 and continued its move higher.


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


The continuation rally has taken the issue all the way to $5.60. That level comes in just above the pair of highs from January 24 ($5.56) and January 25 ($5.53).

Since reaching that elevated level, Egalet's stock has drifted lower into the lower $5.00 handle.

Posted In: TechnicalsIntraday UpdateMoversTrading Ideas